Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The androgen receptor regulates a druggable translational regulon in advanced prostate cancer

ABSTRACT: The androgen receptor regulates a druggable translational regulon in advanced prostate cancer

PROVIDER: PRJNA476967 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR7405200.fastq.gz	Fastqsanger.gz
	SRR7405201.fastq.gz	Fastqsanger.gz
	SRR7405192_1.fastq.gz	Fastqsanger.gz
	SRR7405192_2.fastq.gz	Fastqsanger.gz
	SRR7405202.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 22

Similar Datasets

The androgen receptor regulates a druggable translational regulon in advanced prostate cancer [ribosome profiling]

Project description:The androgen receptor regulates a druggable translational regulon in advanced prostate cancer [ribosome profiling]

| PRJNA476979 | ENA

The androgen receptor regulates a druggable translational regulon in advanced prostate cancer [RNA-seq]

Project description:The androgen receptor regulates a druggable translational regulon in advanced prostate cancer [RNA-seq]

| PRJNA476980 | ENA

The androgen receptor regulates a druggable translational regulon in advanced prostate cancer [RNA-seq]

Project description:The recent advent of highly potent inhibitors of the androgen receptor and androgen biosynthesis has had the unfortunate iatrogenic effect of fueling new lethal prostate cancer phenotypes in patients. In particular, non-neuroendocrine androgen receptor-low castration resistant prostate cancer (AR low CRPC) is increasing in occurrence amongst patients and is uniformly fatal. The mechanisms that promote this phenotype remain poorly understood. Through molecular studies of murine and human models of AR low CRPC, we have identified a new functional interface between the androgen receptor and the translation initiation complex inhibitor 4EBP1. AR directly regulates 4EBP1 expression which translationally represses eIF4F complex formation and a pro-proliferation program. In the context of AR low prostate cancer, de-repression of translation initiation drives the aberrant expression of the pro-proliferation regulon which fuels uncontrolled cell growth. Genetic and pharmacologic inhibition of the downstream eIF4F translation initiation complex reverses the proliferation phenotype in vitro and in vivo. These findings reveal a new previously unrecognized druggable nexus which functionally link the processes of mRNA transcription and translation initiation in a rapidly emerging class of advanced lethal prostate cancer

2019-07-31 | GSE116081 | GEO

The androgen receptor regulates a druggable translational regulon in advanced prostate cancer [ribosome profiling]

2019-07-31 | GSE116082 | GEO

The androgen receptor regulates a druggable translational regulon in advanced prostate cancer.

Project description:The androgen receptor (AR) is a driver of cellular differentiation and prostate cancer development. An extensive body of work has linked these normal and aberrant cellular processes to mRNA transcription; however, the extent to which AR regulates posttranscriptional gene regulation remains unknown. Here, we demonstrate that AR uses the translation machinery to shape the cellular proteome. We show that AR is a negative regulator of protein synthesis and identify an unexpected relationship between AR and the process of translation initiation in vivo. This is mediated through direct transcriptional control of the translation inhibitor 4EBP1. We demonstrate that lowering AR abundance increases the assembly of the eIF4F translation initiation complex, which drives enhanced tumor cell proliferation. Furthermore, we uncover a network of pro-proliferation mRNAs characterized by a guanine-rich cis-regulatory element that is particularly sensitive to eIF4F hyperactivity. Using both genetic and pharmacologic methods, we demonstrate that dissociation of the eIF4F complex reverses the proliferation program, resulting in decreased tumor growth and improved survival in preclinical models. Our findings reveal a druggable nexus that functionally links the processes of mRNA transcription and translation initiation in an emerging class of lethal AR-deficient prostate cancer.

| S-EPMC6746573 | biostudies-literature

The androgen receptor regulates a druggable translational regulon in advanced prostate cancer

Project description:This SuperSeries is composed of the SubSeries listed below.

2019-07-31 | GSE116083 | GEO

The Wnt/β-catenin-signaling pathway is modulated by androgen ablation therapy for advanced clinical prostate cancer and contributes to androgen independent cell growth

Project description:Androgen ablation therapy (AAT) is standard treatment for locally-advanced/metastatic prostate cancer (PCa). Many patients develop castration-resistance (CRPCa) after ~2-3 years, with a poor prognosis. The molecular mechanisms underlying CRPCa progression are unclear. mRNA-Seq was performed on tumours from 7 patients with locally-advanced/metastatic PCa before and ~22 weeks after AAT initiation. Differentially regulated genes were identified in treatment pairs. Tumour biopsies from 7 patients were taken before and after AAT treatment

2013-10-07 | E-GEOD-48403 | biostudies-arrayexpress

The Wnt/β-catenin-signaling pathway is modulated by androgen ablation therapy for advanced clinical prostate cancer and contributes to androgen independent cell growth

2013-10-07 | GSE48403 | GEO

Neuropilin-2 regulates androgen-receptor transcriptional activity in advanced prostate cancer

Project description:Neuropilin-2 regulates androgen-receptor transcriptional activity in advanced prostate cancer

| PRJNA844001 | ENA

Stat5 induces androgen receptor (AR) gene transcription in prostate cancer and offers a druggable pathway to target androgen receptor signaling

Project description:Stat5 induces androgen receptor (AR) gene transcription in prostate cancer and offers a druggable pathway to target androgen receptor signaling

| PRJNA945909 | ENA

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data